[ American Advertising Federation Montgomery ]
Federal Advertising Policy Update: October 2026
AAF National’s October report tracks federal action on AI, kids’ online safety, advertising deductibility, personalized pricing, and pharmaceutical advertising.

Adapted from AAF National’s October 2026 Government Report, by Anne Kierig, Vice President, Government Advocacy & Policy. This post summarizes that report’s October policy snapshot.
With the midterm elections approaching and a short lame-duck session ahead, AAF National is tracking several federal proposals affecting advertising. Here are the report’s main areas of focus.
Artificial intelligence and state-law preemption
The report describes an ongoing debate over whether federal legislation should override state AI laws. It notes that executive and FTC actions have raised preemption questions, while Congress has considered proposals without establishing a broad statutory override.
AAF highlights the FRONTIER Act’s distinction between frontier AI developers and the businesses that deploy or use AI. The proposal described in the report targets certain developer obligations while preserving generally applicable laws and state regulation of deployers and users.
Kids’ online safety
AAF identifies children’s online safety as a major issue for the year-end session. Its report discusses the House KIDS Act, COPPA 2.0 provisions, data-broker requirements, and differences between House and Senate approaches to KOSA. Negotiations may also intersect with state AI preemption proposals.
The report flags potential implications for advertising to teenagers and age-assurance practices across the digital advertising ecosystem.
Advertising deductibility
According to AAF, full deductibility of advertising as an ordinary business expense survived the prior year’s tax legislation. The report warns that proposals to delay or limit deductions could return as lawmakers seek revenue, with pharmaceutical advertising remaining a particular focus.
Personalized pricing
AAF describes an FTC proposed enforcement policy addressing the use of consumer data to individualize prices, discounts, coupons, and loyalty incentives. The report highlights proposed disclosures about personalization and the data used, while distinguishing a policy statement from a trade rule.
Pharmaceutical direct-to-consumer advertising
The report outlines FDA activity involving broadcast drug advertising, the “adequate provision” standard, and fair-balance requirements. It says a proposed rule is expected in December 2026 and that AAF plans to comment once it is published.
Get involved
Advertising professionals can bring their perspective to lawmakers at Advertising Day on the Hill on March 11, 2027.
The November 10 webinar on AI, privacy, and policy offers another opportunity to learn about the issues shaping the industry.
